基蛋生物(603387.SH):擬於2020年度申請綜合授信額度20億元
格隆匯3月23日丨基蛋生物(603387.SH)公佈,根據目前經濟環境及公司經營的總體情況,結合公司2020年度資金使用計劃的需要,公司及全資、控股子公司以信用方式擬於2020年度向各商業銀行申請綜合授信人民幣20億元額度,包括短期流動資金貸款、銀行承兑匯票、商業承兑匯票、保函、信用證等形式,上述綜合授信期限為公司2019年年度股東大會審議通過之日起至2020年度股東大會召開之日止。
以上授信額度不等於公司的實際融資金額,實際融資金額應在授信額度內,並以銀行與公司實際發生的融資金額為準,具體融資金額將視公司運營資金的實際需求來合理確定。授信期限內,授信額度可循環使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.